Department of Pathology Research Division Success Stories
The human intermediate prolactin receptor is a mammary proto-oncogene. Jacqueline M Grible, Patricija Zot, Amy L Olex, Shannon E Hedrick, J Chuck Harrell, Alicia E Woock, Michael O Idowu, Charles V Clevenger
NPJ Breast Cancer. 2021 Mar 26;7(1):37. doi: 10.1038/s41523-021-00243-7.PMID: 33772010
Senthil Radhakrishnan was awarded a grant from the American Cancer Society. "Understanding and Targeting Nrf1 Pathway in Triple-negative Breast Cancer"
$165,000 direct/year for 4 years Co-I: Harrell, Koblinski, Gewirtz, McClay
Justin Craig completed the requirements for a Degree of Doctor of Philosophy in the Clinical and Translational Science Program
Alicia Woock completed the requirements for a Degree of Doctor of Philosophy in the Clinical and Translational Science Program
A publication from Justin Craig, Tia Turner, Chuck Harrell, and Charles Clevenger is the current featured article by the Endocrine Society. https://academic.oup.com/endo
A publication from Tia Turner, Mohammad Alzubi, and Chuck Harrell is included in Scientific Reports Top 100 downloaded cancer papers for 2020, at 25th. https://www.nature.com/collections/aijhgffdjh
Regulatory T Cells Support Breast Cancer Progression by Opposing IFN-γ-Dependent Functional Reprogramming of Myeloid Cells.
Clark NM, Martinez LM, Murdock S, deLigio JT, Olex AL, Effi C, Dozmorov MG, Bos PD.
Cell Rep. 2020 Dec 8;33(10):108482. doi: 10.1016/j.celrep.2020.108482.
Local Targeting of Lung-Tumor-Associated Macrophages with Pulmonary Delivery of a CSF-1R Inhibitor for the Treatment of Breast Cancer Lung Metastases.
Alhudaithi SS, Almuqbil RM, Zhang H, Bielski ER, Du W, Sunbul FS, Bos PD, da Rocha SRP.
Mol Pharm. 2020 Dec 7;17(12):4691-4703. doi: 10.1021/acs.molpharmaceut.0c00983. Epub 2020 Nov 10.
Harrell and Clevenger Labs
Breast cancer liver metastasis: current and future treatment approaches.
Rashid NS, Grible JM, Clevenger CV, Harrell JC.
Clin Exp Metastasis. 2021 Mar 6. doi: 10.1007/s10585-021-10080-4. Online ahead of print.
Prolactin Drives a Dynamic STAT5A/HDAC6/HMGN2 Cis-Regulatory Landscape Exploitable in ER+ Breast Cancer.
Craig JM, Turner TH, Harrell JC, Clevenger CV.
Endocrinology. 2021 Feb 16:bqab036. doi: 10.1210/endocr/bqab036. Online ahead of print.
Harrell and Bos Labs
Unexpected PD-L1 immune evasion mechanism in TNBC, ovarian, and other solid tumors by DR5 agonist antibodies.
Mondal T, Shivange GN, Tihagam RG, Lyerly E, Battista M, Talwar D, Mosavian R, Urbanek K, Rashid NS, Harrell JC, Bos PD, Stelow EB, Stack MS, Bhatnagar S, Tushir-Singh J.
EMBO Mol Med. 2021 Mar 5;13(3):e12716. doi: 10.15252/emmm.202012716. Epub 2021 Feb 15.
MYCN-amplified neuroblastoma is addicted to iron and vulnerable to inhibition of the system Xc-/glutathione axis.
Floros KV, Cai J, Jacob S, Kurupi R, Fairchild CK, Shende M, Coon CM, Powell KM, Belvin BR, Hu B, Puchalapalli M, Ramamoorthy S, Swift K, Lewis JP, Dozmorov MG, Glod J, Koblinski JE, Boikos SA, Faber AC.
Cancer Res. 2021 Jan 22:canres.1641.2020. doi: 10.1158/0008-5472.CAN-20-1641. Online ahead of print.
Conformational Modulation of Iduronic Acid-Containing Sulfated Glycosaminoglycans by a Polynuclear Platinum Compound and Implications for Development of Antimetastatic Platinum Drugs.
Gorle AK, Haselhorst T, Katner SJ, Everest-Dass AV, Hampton JD, Peterson EJ, Koblinski JE, Katsuta E, Takabe K, von Itzstein M, Berners-Price SJ, Farrell NP.
Angew Chem Int Ed Engl. 2021 Feb 8;60(6):3283-3289. doi: 10.1002/anie.202013749. Epub 2020 Dec 23.
Hsp70 acts as a fine-switch that controls E3 ligase CHIP-mediated TAp63 and ΔNp63 ubiquitination and degradation.
Wu HH, Wang B, Armstrong SR, Abuetabh Y, Leng S, Roa WHY, Atfi A, Marchese A, Wilson B, Sergi C, Flores ER, Eisenstat DD, Leng RP.
Nucleic Acids Res. 2021 Feb 22:gkab081. doi: 10.1093/nar/gkab081. Online ahead of print.
Human Papillomavirus 16 (HPV16) E2 Repression of TWIST1 Transcription Is a Potential Mediator of HPV16 Cancer Outcomes.
Fontan CT, Das D, Bristol ML, James CD, Wang X, Lohner H, Atfi A, Morgan IM.
Loss of Jag1 cooperates with oncogenic Kras to induce pancreatic cystic neoplasms.
Chung WC, Challagundla L, Zhou Y, Li M, Atfi A, Xu K.
Life Sci Alliance. 2020 Dec 2;4(2):e201900503. doi: 10.26508/lsa.201900503. Print 2021 Feb.
Youngman Oh, (pictured) School of Medicine VETAR grant. “Development of a novel targeted therapy for age-related macular degeneration”. A MultiPI application with Dr. Qinggu Xu in Pharmaceutics to investigate therapeutic potential of IGFBP-3R mAb for dry AMD using a sodium iodate AMD mouse model.
Michael Idowu and Chuck Harrell are Co-Investigators on a R01 from the NCI, with PI David Gewirtz (Pharmacology): A sequential therapeutic strategy of senescence induction and senolytics for elimination of surviving residual breast tumor cells. $3.3M
Chuck Harrell served on the NIH MCT2 study section March 3-5.
Gift from Helene Fuld Health Trust supports scholarships for master’s students at the VCU School of Nursing.
Black Americans experienced highest per capita excess death rates, while regional surges contributed to higher excess death rates from COVID-19 and other causes, a VCU-led JAMA study finds.
A new study led by VCU researchers surveyed 788 people. Among its findings: Older people were less likely to support donating vaccines, as were Republicans.
A VCU Wilder School institute is playing a key role in the state’s efforts to distribute the COVID-19 vaccine equitably
“If we have a relative rate of vaccination that’s aligned with our relative rate of infection and death, that’s a more equitable approach.”
Only 15% of U.S. medical schools offer competency-based graduation. These programs allow students to graduate in 3 years instead of 4, and can help reduce student debt and address physician shortages.
Working behind the scenes of clinical trials and medical research, VCU data specialists get treatments to patients faster.
Leaders of a new educational series say learning, reflecting and involving the community are vital to determining how VCU and VCU Health take action toward achieving health equity.
The Alumni Lunch and Learn series featured M. Norman Oliver, who said the state is in a race against the two new COVID-19 variants.